CompletedPhase 1NCT00842452
Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery
Studying Endometrial stromal sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Steven Waggoner, MD
- Principal Investigator
- Stephen Waggoner, MD, MD,PHDCase Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
- Intervention
- topotecan hydrochloride(drug)
- Enrollment
- 26 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2009 – 2011
Study locations (1)
- Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00842452 on ClinicalTrials.govOther trials for Endometrial stromal sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07467772Ph 2 Elacestrant in ER Positive Uterine SarcomasDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT03624244Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)Centre Leon Berard
- RECRUITINGNCT00005095Specimen and Data Study for Ovarian Cancer Early Detection and PreventionNorthwestern University